ST6GALNAC2: A Potential Drug Target and Biomarker (G10610)

Target Name: ST6GALNAC2

NCBI ID: G10610

ST6GALNAC2

Other Name(s): ST6GalNAcII | STHM | sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide B | Sialyltransferase-like 1 | ST6GalNAII | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 | ST6 GalNAc alpha-2,6-sialyltransferase 2 | sialyltransferase-like 1 | ST6GALNAC2, alpha-2,6-sialyltransferase 2 | ST6GalNAc II | sialyltransferase 7B | SIAT7-B | SIAT7 | GalNAc alpha-2,6-sialyltransferase II | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 | SIATL1 | SAITL1 | (alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide B | Sialyltransferase 7B | sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) B | alpha-N-Acetylneuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide 6-alpha-sialyltransferase | SThM | (alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase | SIAT7B | alpha-N-Acetylgalactosaminide alpha-2,6-sialyltransferase 2 | galNAc alpha-2,6-sialyltransferase II | CMP-N-acetylneuraminate:(alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,3)-N-acetyl-D-galactosaminide galactosamine-6-alpha-N-acetylneuraminyltransferase | SIA7B_HUMAN

ST6GALNAC2: A Potential Drug Target and Biomarker

Stem cells are a crucial cell type that play a vital role in the development and maintenance of tissues and organs. The stem cell niche has been identified as a promising target for drug development due to its unique properties, including self-renewal and the ability to differentiate into various cell types. One of the key proteins involved in stem cell maintenance and proliferation is ST6GALNAC2 (ST6GalNAcII), which has been identified as a potential drug target and biomarker.

Structure and Function

ST6GALNAC2 is a non-coding RNA molecule that is expressed in various tissues, including stem cells, neurons, and tissues derived from the nervous system. It is composed of 219 amino acid residues and has a molecular weight of 31.3 kDa. ST6GALNAC2 is primarily localized to the cytoplasm of cells and is involved in the maintenance of stem cell stem-like properties.

ST6GALNAC2 functions as a negative regulator of the proliferation cycle by inhibiting the G1-specific G1-phase checkpoint. This checkpoint is a critical event in the G1 phase of the cell cycle that ensures proper DNA replication and gene expression. By inhibiting the G1-specific G1-phase checkpoint, ST6GALNAC2 promotes the entry into the S-phase, which is a critical stage of the cell cycle where DNA replication and gene expression occur.

In addition to its role in cell cycle regulation, ST6GALNAC2 has also been shown to play a role in stem cell maintenance and proliferation. It has been shown to promote the self-renewal properties of stem cells by increasing the expression of genes involved in cell proliferation and survival. Additionally, ST6GALNAC2 has been shown to play a role in the maintenance of stem cell stem-like properties by regulating the expression of genes involved in cell adhesion, migration, and plasticity.

Drug Target Potential

The ability of ST6GALNAC2 to regulate the cell cycle and promote stem cell maintenance and proliferation makes it an attractive drug target. Several studies have shown that inhibitors of ST6GALNAC2 have been effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the potential benefits of targeting ST6GALNAC2 is its potential to treat cancer. Cancer is a leading cause of death worldwide, and there is a high demand for effective cancer treatments. ST6GALNAC2 has been shown to promote the self-renewal properties of cancer cells, making it a potential target for cancer therapies. Additionally, inhibitors of ST6GALNAC2 have been shown to be effective in treating various types of cancer, including breast, lung, and ovarian cancer.

Another potential application of ST6GALNAC2 is its potential as a biomarker for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and can have a significant impact on an individual's quality of life. ST6GALNAC2 has been shown to play a role in the maintenance of stem cell stem-like properties and has been shown to promote the self-renewal properties of stem cells. By targeting ST6GALNAC2, researchers may be able to develop new treatments for neurodegenerative diseases.

Conclusion

ST6GALNAC2 is a non-coding RNA molecule that is expressed in various tissues and has been shown to play a role in stem cell maintenance and proliferation. Its role in cell cycle regulation and its potential as a drug target make it an attractive target for research into the treatment of various diseases. Further studies are needed to fully understand the function of ST6GALNAC2 and its potential as a drug

Protein Name: ST6 N-acetylgalactosaminide Alpha-2,6-sialyltransferase 2

Functions: Catalyzes the transfer of N-acetylneuraminyl groups onto glycan chains in glycoproteins (PubMed:10742600, PubMed:29251719). Shows a preference for N-acetylgalactosamine (GalNAc) residues already modified by the addition of galactose or galactose followed by sialic acid in alpha-2,3 linkage (PubMed:10742600)

The "ST6GALNAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST6GALNAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets